BioAge Labs (NASDAQ:BIOA) Upgraded by BTIG Research to “Strong-Buy” Rating

BTIG Research upgraded shares of BioAge Labs (NASDAQ:BIOA) to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports.

A number of other research firms also recently issued reports on BIOA. Wall Street Zen upgraded shares of BioAge Labs from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Needham & Company LLC started coverage on shares of BioAge Labs in a research note on Friday, March 27th. They set a “buy” rating and a $50.00 price objective for the company. Citigroup boosted their price objective on shares of BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Oppenheimer started coverage on shares of BioAge Labs in a research note on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $45.00.

BioAge Labs Stock Performance

BioAge Labs stock opened at $19.14 on Wednesday. BioAge Labs has a 1 year low of $3.67 and a 1 year high of $24.00. The firm has a 50 day moving average price of $18.25 and a 200 day moving average price of $15.73. The company has a market cap of $850.83 million, a price-to-earnings ratio of -7.97 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The firm had revenue of $2.77 million during the quarter. Sell-side analysts predict that BioAge Labs will post -2.69 EPS for the current year.

Institutional Investors Weigh In On BioAge Labs

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after buying an additional 93,694 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in shares of BioAge Labs during the fourth quarter worth $13,892,000. Geode Capital Management LLC lifted its position in shares of BioAge Labs by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock worth $7,826,000 after purchasing an additional 28,646 shares in the last quarter. State Street Corp lifted its position in shares of BioAge Labs by 113.4% during the fourth quarter. State Street Corp now owns 422,846 shares of the company’s stock worth $5,594,000 after purchasing an additional 224,735 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of BioAge Labs during the fourth quarter worth $5,406,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.